Shockwave Medical to Present Latest Research at EuroPCR 2025

May 15, 2025 – Shockwave Medical, Inc., part of Johnson & Johnson MedTech and a global leader in the field of circulatory restoration, has announced that data from 23 company-sponsored and funded studies, including three late-breaking presentations, will be presented at EuroPCR 2025, May 20-23 in Paris. These studies will feature data from Shockwave’s cardiovascular portfolio, including its market-leading Shockwave Intravascular Lithotripsy (IVL) platform and innovative Reducer technology that are transforming the treatment of cardiovascular disease.¹

“The breadth of research data being presented on our products at EuroPCR 2025 reflects our relentless drive to address the unmet needs of patients suffering from cardiovascular disease,” said Nick West, M.D., Chief Medical Officer, Shockwave Medical. “As a pioneer in IVL and coronary sinus reduction technologies, we are committed to harnessing these clinical insights to drive innovations that will shape new standards of treatment and help physicians improve treatment for their patients worldwide.”

Key data highlights are outlined below. 

• Late-Breaking Presentations:
  • EMPOWER CAD Study: Women with Calcified Coronary Arteries Treated with IVL presented by Margaret McEntegart, M.D., Columbia University Medical Center. EMPOWER CAD is a prospective, multi-center, all-female study investigating the use of coronary intravascular lithotripsy (IVL) for treating calcified lesions in women with coronary artery disease. It aims to confirm the benefits of IVL in a post-market, real-world, all-comers population of female patients.
  • Randomized Comparison of Lithotripsy vs. Conventional Preparation of Calcified Lesions (BALI) presented by Andreas Torp Kristensen, M.D., Arhus University Hospital. BALI is a multicenter, randomized trial that will show whether routine addition of balloon lithotripsy improves outcomes compared with conventional preparation alone.
  • Rotational Atherectomy, Lithotripsy or Laser for Calcified Coronary Stenosis. One-Year Outcomes (RollerCoastr-EPIC22)² presented by Alfonso Jurado, M.D., Ph.D., La Paz University Hospital. RollerCoastr-EPIC22 is a randomized controlled trial that is investigating the effectiveness of rotational atherectomy (RA), excimer laser coronary angioplasty (ELCA), and intravascular lithotripsy (IVL) in treating calcified coronary stenosis, with a focus on one-year outcomes.
• Poster Presentation: Coronary Sinus Reducer for Patients with Refractory Angina and Non-Obstructive Coronary Disease presented by Ranil de Silva, M.D., Imperial College London.

In addition to the data being presented at EuroPCR, Shockwave Medical will support educational programs, in-booth presentations and training opportunities for attendees throughout the meeting, including two sponsored session symposia:

• Treat Calcium Right the First Time: New Considerations for PCI Planning and Device Selection to Optimize Outcomes. Attendees will explore the role of IVL as a first-line treatment strategy for managing coronary artery calcification (CAC) by observing a recorded case and listening to a panel discussion.
  • Moderator: Emanuele Barbato, M.D., Sant’Andrea University Hospital
  • Panelists:
    • Angela McInerney, M.D., University Hospital Galway
    • Margaret McEntegart, M.D., Columbia University Medical Center
    • Niels Tuhe Olsen, Rigshospitalet
    • Marco Pavani, M.D., AOU San Luigi Gonzaga
    • Simon Wilson, M.D., St George’s University NHS Trust
• Road to Relief – Effective Treatment for Patients with Refractory Angina with Shockwave Reducer. Attendees will hear from panelists to understand the true impact and occurrence of refractory angina, a major public health problem that has a treatment option.
  • Moderator: James Spratt, M.D., St. George’s University NHS Trust
  • Panelists:
    • Ranil de Silva, M.D., Royal Brompton Hospital
    • Mariusz Tomaniak, M.D., Ph.D., FESC, Medical University of Warsaw
    • Felix Woitek, M.D., University Hospital Carl Gustav Carus Dresden Heart Center
    • Tommaso Gori, M.D., Ph.D., University Medical Center Johannes Gutenberg University Mainz

Finally, Shockwave Medical’s IVL and Reducer technology will be prominently showcased across 13 scientific sessions of interest:

• Coronary Sinus Reducer Implantation: When All is Not Lost presented by Kevin Cheng
• Optimizing our Approach to Calcium Treatment – The Exchange presented by Breda Hennessey and Yongcheol Kim
• Calcified Nodules: A Different Beast? presented by Emanuele Barbato
• A National Audit of Coronary Sinus Reducer Implantation in the United Kingdom presented by Kevin Cheng
• Safety and Efficacy of Intravascular Lithotripsy for Calcified Left Main Disease: A Subgroup Analysis of Shock India Registry presented by Ankush Gupta
• Coronary Lithotripsy in Calcified Lesions: Preliminary Results from the GISE Shockcalcium Registry presented by Guilia Nardi
• Treatment of Refractory Angina Pectoris Associated with Coronary Microcirculation Dysfunction presented by Szymon Wlodarczak
• Calcium Modification: Contemporary Comparisons of Atherectomy and IVL presented by Pedro Lemos and Sheeran Al Shaikh
• Coronary Sinus Reducer for Patients with Refractory Angina & Non-Obstructive Coronary Disease (REDUCER I – ANOCA) presented by Ranil de Silva
• FRANCE-LILI Registry: Advancing Intravascular Lithotripsy in In-Stent Restenosis Treatment presented by Guillaume Cayla
• Efficacy of CS Reducer in Refractory Angina Pectoris Associated with Microvascular Dysfunction presented by Szymon Wlodarczak
• Effectiveness of Coronary Sinus Reducer Implantation in a Routine Clinical Practice: 12-month Outcomes presented by Szymon Wlodarczak
• Intravascular Coronary Lithotripsy Prior to DCB Angioplasty presented by Franz Kleber

Learn more about Shockwave Medical and its portfolio online.

1: Shockwave Medical’s Reducer technology is under clinical evaluation in the U.S. and CE Marked in the European Union and United Kingdom.
2: RollerCoastr-EPIC-22 is not a Shockwave Medical-sponsored study.